Error loading player: No playable sources found
4200
Update on MASLD Therapies Pipeline
Date
May 5, 2025
This product is not available for individual purchase, but it is available as part of the following products:
Don't miss the opportunity to access the latest research and discoveries in the field of digestive diseases. DDW On Demand is a valuable and convenient way to enhance your knowledge and skills in digestive disease care…
Society: AASLD
This State-of-the-Art session provides a timely update on the evolving MASLD therapies pipeline, featuring insights into emerging pharmacologic agents and real-world data on current treatments. Topics include the impact of SGLT-2 and GLP-1 receptor agonists on cirrhosis outcomes, eligibility criteria for resmetirom therapy, and phase 2 results for efimosfermin alfa in MASH with fibrosis.
This State-of-the-Art session provides a timely update on the evolving MASLD therapies pipeline, featuring insights into emerging pharmacologic agents and real-world data on current treatments. Topics include the impact of SGLT-2 and GLP-1 receptor agonists on cirrhosis outcomes, eligibility criteria for resmetirom therapy, and phase 2 results for efimosfermin alfa in MASH with fibrosis.
Moderators
Icahn School of Medicine at Mount Sinai
University of California, San Francisco
Related Products
